Literature DB >> 8491296

Density of phenotypic markers on BAL T-lymphocytes in hypersensitivity pneumonitis, pulmonary sarcoidosis and bronchiolitis obliterans with organizing pneumonia.

N Satake1, S Nagai, A Kawatani, H Kaneshima, S Tanaka, M Takeuchi, T Izumi.   

Abstract

In vitro studies have shown that the density of surface antigens reflects the degree of activation of T-cells. We therefore studied the density of surface antigens on T-cells from bronchoalveolar lavage fluid (BALF) and blood in patients with sarcoidosis, hypersensitivity pneumonitis (HP) and bronchiolitis obliterans with organizing pneumonia (BOOP). BALF cells were stained with anti-CD3, anti-CD4, anti-CD8 and anti-human leucocyte antigen-DR(HLA-DR) monoclonal antibodies, and were analysed by cytoflowmetry. The density was evaluated by measuring the Mean Channel fluorescence intensity of the stained cells. The results demonstrated a significant increase in the CD3 density in patients with hypersensitivity pneumonitis (108.2 +/- 20.2 MC), compared with those with pulmonary sarcoidosis (51.2 +/- 12.6), BOOP (74.5 +/- 29.3), and healthy controls (57.1 +/- 11.5). Similar results were obtained for the CD4 and CD8 density in patients with HP. Although the number of HLA-DR positive cells was increased, the density was lower in patients with sarcoidosis (57.4 +/- 11.6) and hypersensitivity pneumonitis (57.4 +/- 14.8), than in healthy controls (72.2 +/- 15.1). Comparable changes were not observed in the peripheral blood. These results suggest that T-cell activation in hypersensitivity pneumonitis may be associated with an increase in the CD3, CD4, and CD8 density on BALF T-cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8491296

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  4 in total

1.  Pneumonitis: a serious adverse effect of PD-L1 inhibitors including pembrolizumab.

Authors:  Frances Rickard; Catherine Hyams; Andrew T Low
Journal:  BMJ Case Rep       Date:  2018-05-07

2.  Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.

Authors:  Myriam Delaunay; Jacques Cadranel; Amélie Lusque; Nicolas Meyer; Valérie Gounant; Denis Moro-Sibilot; Jean-Marie Michot; Judith Raimbourg; Nicolas Girard; Florian Guisier; David Planchard; Anne-Cécile Metivier; Pascale Tomasini; Eric Dansin; Maurice Pérol; Marion Campana; Oliver Gautschi; Martin Früh; Jean-David Fumet; Clarisse Audigier-Valette; Sébastien Couraud; Stéphane Dalle; Marie-Thérèse Leccia; Marion Jaffro; Samia Collot; Grégoire Prévot; Julie Milia; Julien Mazieres
Journal:  Eur Respir J       Date:  2017-08-10       Impact factor: 16.671

3.  Lessons from Mycobacterium avium complex-associated pneumonitis: a case report.

Authors:  Victor Zota; Sheryn M Angelis; Armando E Fraire; Ciaran McNamee; Shasta Kielbasa; Daniel H Libraty
Journal:  J Med Case Rep       Date:  2008-05-13

4.  Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline.

Authors:  Ganesh Raghu; Martine Remy-Jardin; Christopher J Ryerson; Jeffrey L Myers; Michael Kreuter; Martina Vasakova; Elena Bargagli; Jonathan H Chung; Bridget F Collins; Elisabeth Bendstrup; Hassan A Chami; Abigail T Chua; Tamera J Corte; Jean-Charles Dalphin; Sonye K Danoff; Javier Diaz-Mendoza; Abhijit Duggal; Ryoko Egashira; Thomas Ewing; Mridu Gulati; Yoshikazu Inoue; Alex R Jenkins; Kerri A Johannson; Takeshi Johkoh; Maximiliano Tamae-Kakazu; Masanori Kitaichi; Shandra L Knight; Dirk Koschel; David J Lederer; Yolanda Mageto; Lisa A Maier; Carlos Matiz; Ferran Morell; Andrew G Nicholson; Setu Patolia; Carlos A Pereira; Elisabetta A Renzoni; Margaret L Salisbury; Moises Selman; Simon L F Walsh; Wim A Wuyts; Kevin C Wilson
Journal:  Am J Respir Crit Care Med       Date:  2020-08-01       Impact factor: 30.528

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.